Regenerative peptide therapy to accelerate pressure ulcer healing
Ended Project Grant Awarded Last action
- Award ID
- R43AG090115
- Recipient
-
Adepthera LLC UEI QDWUGUNKHMT5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $367,000
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Adrenomedullin (ADM) and cgrp family peptides play pivotal roles in regulating angiogenesis, vasculogenesis, and tissue regeneration. Although wild-type ADM and cgrp improve wound healing in a variety of injury models, they are poor drug candidates for the chronic treatment of different disorders. Our recent study of super-agonistic ADM analogs, which self-assemble to form liquid nanogels in situ, suggested these analogs are ideal candidates for mitigating tissue damage and accelerating wound healing in patients with bed sores or nonhealing pressure ulcers. Notably, the self-assembled analog GEL has a 100% loading capacity and allows localized treatment via its multi-faceted regenerative actions. Ideally, the proposed analog GEL therapy would be administered weekly or biweekly subcutaneously in the wound area to improve local blood circulation and accelerate wound healing. The specific aims of this phase I study include identifying an ideal analog GEL formulation and dose range that promotes vascular bed circulation but avoids an effect on systemic hemodynamics in aging diabetic mice (aim 1). Once the ideal analog GEL is identified, we will evaluate whether the analog GEL treatment correlates with enhanced healing functions in aging mice with hindlimb ischemia injury or pressure-induced skin ulcers. We will also compare the analog GEL with pdgf, the only FDA-approved growth factor for wound care, thereby completing the lead optimization process.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$577 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $367,577 |
Quick answers
Who received award R43AG090115?
R43AG090115 was awarded to Adepthera LLC by National Institute on Aging (National Institutes of Health) on September 15, 2024.
How much is award R43AG090115 worth?
$367,000 has been obligated on R43AG090115.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award